Document is current
Any future updates will be listed below
-
Authors
AlSultan, Dalal
Kavanagh, Emma
O’Grady, Shane https://orcid.org/0000-0002-4468-9298
Eustace, Alex J
Castell, Alina
Larsson, Lars-Gunnar
Crown, John
Madden, Stephen F
Duffy, Michael J
-
Funding
Funding for this research was provided by:
Cancer Clinical Research Trust
Irish Research Council (EPSPG/2019/507)
- License Information
-
More Information
Article History
Received: 7 September 2020
Accepted: 6 October 2020
First Online: 14 October 2020
Compliance with ethical standards
:
: DA, SO’G, EK, AJE, AC, LGL, SM & MJD have no conflicts of interest. JC has received honoraria from Eisai, Amgen, Puma Biothechnology, Seattle Genetics, Boehringer Ingelheim, Pfizer, Vertex and Genomic Health. He has acted in an advisory/consulting role to Eisai, Puma Biotechnology, Boehringer Ingelheim, Pfizer, Vertex, Roche. He also serves on the Speakers’ Bureau for Pfizer, Eisai and Genomic Health and has received Research Funding from Roche, Eisai, Boehringer Ingelheim and Puma Biotechnology. In addition, he has received travel, accommodation and expenses from MSD, Pfizer, Roche, AstraZeneca, Abbvie and Novartis. Finally, he is an employee of OncoMark, has stocks in OncoMark and is named on patent WO2020011770 (A1) - A method of predicting response to treatment in cancer patients.
: This study utilised commercially available cell lines and bioinformatics analysis of previously published, publicly available databases. No human or animal subjects were used in this study.
: For this type of study, formal consent is not required.
